Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

US-based biotechnology company Integral Molecular will leverage its technology platforms to identify Covid-19 vaccines and therapeutics.

Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array will be used to gain insights into the human immune response to the novel coronavirus.

The company will also utilise the platforms to discover cellular receptors that could provide information on the rapid spread of the virus.

Integral Molecular president Benjamin Doranz said: “Deep expertise in virology is at the core of Integral Molecular’s nearly 20-year history, including our contributions to discovering the receptor for HIV and other viruses.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We have the ability to use our unique tools to help curb the spread of this deadly virus and have initiated research efforts on multiple fronts to aid in the global effort for a coronavirus vaccine.”

During previous emerging epidemics such as Ebola and Zika, Integral Molecular supported discovery efforts for vaccines and therapeutics.

The Shotgun Mutagenesis Epitope Mapping technology mapped more than 1,000 antibody binding sites to date, while the Membrane Proteome Array platform helped find various receptors used by viruses to infect cells.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact